Brequinar sodium, mycophenolic acid, and cyclosporin A inhibit different stages of IL-4- or IL-13-induced human IgG4 and IgE production in vitro.
We investigated the effect of cyclosporin A (CsA), mycophenolic acid (MPA), and brequinar sodium (BQ) on human IgG4 and IgE synthesis induced by IL-4 or IL-13. BQ inhibited IL-4 and IL-13-induced IgG4 and IgE synthesis in cultures of peripheral blood mononuclear cells (PBMC) or highly purified B cells costimulated by anti-CD40 mAbs in a dose-dependent fashion. CsA and MPA had either suppressive or enhancing effects depending on the concentrations tested. Interestingly, BQ inhibited IgG4 and IgE synthesis at concentrations of 10(-6)-10(-8) M, which did not affect T or B cell proliferation, indicating that the inhibitory effects of BQ on Ig production were not directly related to inhibition of T or B cell proliferation. In contrast, the inhibitory effects of MPA on Ig production were directly associated with inhibitory effects on T and B cell proliferation. CsA blocked T and B cell proliferation at the same concentration (10(-7) M) which enhanced IgG4 and IgE synthesis, indicating that reduction in T or B cell proliferation correlated with enhanced IgE production. CsA also inhibited CD40 ligand expression and IL-2, IL-4, IL-5, IFN-gamma, and GM-CSF production by activated CD4+ T cell clones, whereas MPA and BQ were ineffective, indicating that these compounds do not inhibit early events in T cell activation. Collectively, our data indicate that BQ, MPA, and CsA block different stages of the IgG4 and IgE production process. In addition, we observed that CsA and MPA, in contrast to BQ, at lower concentrations can also have potentiating effects on the production of these Ig isotypes.
Chang
C C
CC
DNAX Research Institute of Molecular and Cellular Biology, Human Immunology Department, Palo Alto, California 94304-1104.
Aversa
G
G
Punnonen
J
J
Yssel
H
H
de Vries
J E
JE
D015703:Antigens, CD / Q000032:analysis / Q000502:physiology; D000944:Antigens, Differentiation, B-Lymphocyte / Q000032:analysis / Q000502:physiology; D001713:Biphenyl Compounds / Q000494:pharmacology*; D019013:CD40 Antigens; D002478:Cells, Cultured; D016572:Cyclosporine / Q000494:pharmacology*; D016207:Cytokines / Q000096:biosynthesis; D006801:Humans; D007073:Immunoglobulin E / Q000096:biosynthesis*; D007074:Immunoglobulin G / Q000096:biosynthesis* / Q000145:classification; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D018793:Interleukin-13; D015847:Interleukin-4 / Q000494:pharmacology; D007378:Interleukins / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D009173:Mycophenolic Acid / Q000494:pharmacology*; D011798:Quinaldines
D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; D001713:Biphenyl Compounds; D019013:CD40 Antigens; D016572:Cyclosporine; D016207:Cytokines; D007073:Immunoglobulin E; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018793:Interleukin-13; D015847:Interleukin-4; D007378:Interleukins; D009173:Mycophenolic Acid; C046943:brequinar; D011798:Quinaldines